Therapeutic effect of Topical Sirolimus on Facial Angiofibromas in Patients of Tuberous Sclerosis Complex
| Autor: | Leena HN, Savitha B Raghavan, Yogesh HR, Sujatha Sowmyanarayan, Amberkar Mohanbabu Vittalrao, Abhineetha Hosthota |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Perspectives In Medical Research, Vol 12, Iss 1, Pp 45-48 (2024) |
| Druh dokumentu: | article |
| ISSN: | 2348-1447 2348-229X |
| DOI: | 10.47799/pimr.1201.09 |
| Popis: | Introduction: Tuberous sclerosis complex (TSC) is a rare autosomal dominant disorder. Facial angiofibromas are the most common cutaneous findings of TSC. Treatment modalities such as laser, surgery, and/or cryotherapy are employed. Topical therapy with Sirolimus, an mTOR inhibitor, showed beneficial effects. Objective: To study the effects of topical sirolimus (0.1%) on Facial Angiofibromas in patients of TSC. Methodology: Four patients with facial angiofibromas were included. They applied Sirolimus preparation twice daily, for 3 months. The Facial Angiofibroma Severity Index (FASI) was recorded pre-intervention, at 3 months and after 6 months. Results: All the patients showed a reduction in the FASI score at the end of three months of therapy. In three patients, on discontinuing therapy, there was no change in the FASI score at the end of six months, i.e., FASI 3 and FASI 6 were the same. Conclusion: Topical sirolimus is an effective treatment for facial angiofibroma in patients with TSC. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|